Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 13fludarabine phosphate 8Etoposide 8Methotrexate 7Idarubicin 6Daunorubicin 6Busulfan 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Vorinostat 4Tacrolimus 4Mitoxantrone 4Cyclophosphamide 4Azacitidine 4Antilymphocyte Serum 4merphos 3Topotecan 3Thioguanine 3Cyclosporine 3sargramostim 2laromustine 2Specimen Handling 2Radiotherapy 2Methylprednisolone 2Lenalidomide 2Hydrocortisone 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anemia, Refractory, with Excess of Blasts × TAK-243 × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡